Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2024-04-19 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
《董事会审计委员会工作细则》
Governance Information Classification · 95% confidence The document is titled '董事会审计委员会工作细则' which translates to 'Board Audit Committee Working Rules'. It details the structure, responsibilities, and procedures of the audit committee within the board of directors of the company. It references company governance, audit oversight, and internal control supervision but does not contain any financial statements, audit reports, or financial results. It is a governance-related document outlining internal rules and committee functions rather than a report or announcement of financial data or voting results. Therefore, it fits best under Governance Information (CGR). The document length is 2711 characters, which is relatively short but contains substantive governance content, not just an announcement or certification.
2024-04-19 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a statement from the board regarding the independence of the company's independent directors, referencing regulatory rules about independent directors and their independence evaluation. It does not contain financial data, audit results, or detailed management reports. It is a governance-related announcement about board members' independence compliance. The document length is short (510 characters), and it is a specific opinion on director independence, which fits best under Governance Information (CGR).
2024-04-19 Chinese
《董事会议事规则》
Governance Information Classification · 100% confidence The document is titled '赛隆药业集团股份有限公司 董事会议事规则' which translates to 'Sailong Pharmaceutical Group Co., Ltd. Board Meeting Rules'. It details the rules and procedures for the company's board of directors meetings, including composition, powers, meeting convocations, voting procedures, and record keeping. There is no financial data, no report of financial results, no announcement of voting results, no management changes, no legal proceedings, no capital updates, and no earnings information. The content is focused on governance practices and internal rules for board operations. Therefore, this document fits the category of Governance Information (CGR). The document length is sufficient and the content is substantive, not a mere announcement or certification.
2024-04-19 Chinese
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed financial data including main business activities, accounting data for the last three years, quarterly financial data, shareholder information, and notes on accounting policy changes. The length of the document (9061 characters) and the presence of substantive financial data and analysis confirm it is a financial report rather than a brief announcement or a certification. The document is a summary of the full annual report, which is typical for an Annual Report (10-K) filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2023
2024-04-19 Chinese
2023年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度董事会工作报告" which translates to "2023 Annual Board of Directors Work Report." It details the activities, meetings, and decisions of the board of directors throughout the year 2023, including summaries of financial performance, governance, and future plans. The content focuses on the board's work and governance rather than full financial statements or audit results. It is a comprehensive report on board activities rather than a full annual report or audit report. This fits the category of Board/Management Information (MANG), which covers announcements about board activities and management information. The document length is 3773 characters, which is sufficient for a detailed board report but not a full annual report. Therefore, the classification is MANG with high confidence.
2024-04-19 Chinese
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of the company, including the date, location, agenda items, voting procedures, and proxy forms. It does not contain financial statements or results but rather the announcement and procedural information for the AGM. The document length is 4617 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2024-04-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.